Proactive Investors - Run By Investors For Investors

LeanLife Health continues in-house testing of its omega-3 products, reprices warrants

The study determined the totox value, a parameter for assessing the quality of edible oils
Omega 3 pills on a spoon
LeanLife’s flavorless omega product is plant-based and extracted from flaxseeds

LeanLife Health Inc (CSE:LLP) reported the results of its in-house testing of omega samples, conducted at the company’s small laboratory facility.

The company develops omega-3 products which can be formulated as liquids, emulsions or powders and used as food additives.

READ: BioTime shares pop following positive preclinical results from its HyStem drug delivery platform

Its flavorless omega product is plant-based and extracted from flaxseeds.

The study aimed to determine the totox value, which is a measure of an oil’s oxidation state and a parameter for assessing the quality of edible oils.

The lower the totox value, the better the quality of the oil.

The study determined the totox value of a 10-month-old sample representative of its BioCube machine, was 11.70.

Seven out of the nine samples contained ethanol levels from 0.5% to 2.5%, while the allowable limit in Canada is 0.5%.

The omega-3 market is expected to reach US$7.32 billion by 2020, according to a report by Grand View Research Inc.

The company also announced that it wants to reprice around 9.34 million of its warrants expiring December 15, 2018, from $0.15 each to $0.075 each, extending the expiry date to December 15, 2020.

Shares of the Vancouver-based company were up more than 11% to C$0.05 by Tuesday’s closing bell.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

View full LLP profile View Profile

LeanLife Health Timeline

Newswire
February 07 2019

Related Articles

Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
young girl with allergy
March 22 2019
The sell-off that followed the recent disappointment of Allergy’s PQ Birch jab means now might be a good time to invest, according to City broker finnCap
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use